Analytical and clinical evaluation of biomarkers assays: When are biomarkers ready for prime time?

Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95.

Voelkerding KV Dames SA Durtschi JD . Next-generation sequencing: From basic research to diagnostics. Clin Chem 2009; 55(4): 641–58.

US Food and Drug Administration. Draft guidance for industry: Qualification process for drug development tools, 2010. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf (accessed 27 January 2013).

US Food and Drug Administration. Guidance for industry: Clinical pharmacogenomics: Premarket evaluation in early-phase clinical studies and recommendations for labeling, 2013. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM337169.pdf (accessed 8 February 2013).

Woodcock J . Assessing the clinical utility of diagnostics used in drug therapy. Clin Pharmacol Ther 2010; 88(6): 765–73.

US Food and Drug Administration. Draft guidance for industry and food and drug administration staff – In vitro companion diagnostic devices (released 14 July 2011), 2011. Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm262292.htm (accessed 28 January 2013).

US Food and Drug Administration. Guidance for industry, enrichment strategies for clinical trials to support approval of human drugs and biological products, draft guidance, 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf (accessed 6 February 2013).

US Food and Drug Administration. Draft guidance for industry, clinical investigators, and food and drug administration staff – Design considerations for pivotal clinical investigations for medical devices, 2011. Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm265553.htm (accessed January 2013).

Begg CB . Biases in the assessment of diagnostic tests. Stat Med 1987; 6: 411–23.

Delgado-Rodríguez M Llorca J . Bias. J Epidemiol Community Health 2004; 58: 635–41.

Pepe MS . The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford University Press, Oxford, 2003.

Zhou XH Obuchowski NA McClish DK . Statistical Methods in Diagnostic Medicine. Wiley, New York, 2002.

Gerke O Hoilund-Carlsen PF Poulsen MH Vach W . Interim analyses in diagnostic versus treatment studies: Differences and similarities. Am J Nucl Med Mol Imaging 2012; 2(3): 344–52.

Campbell G Pennello G Yue L . Missing data in the regulation of medical devices. J Biopharm Stat 2011; 21: 180–95.

Pennello G . Bayesian analysis of diagnostic test accuracy when disease state is unverified for some subjects. J Biopharm Stat 2011; 21: 954–70.

Bossuyt PM Reitsma JB Bruns DE . Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. Clin Chem 2003; 49(1): 1–6.

McShane LM Altman DG Sauerbrei W . Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16): 1180–84.

Moher D Schulz KF Altman D . The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285: 1987–91.

Janssens ACJW Ioannidis JPA Van Duijn CM . Strengthening the reporting of genetic risk prediction studies (GRIPS): Explanation and elaboration. BMJ 2011; 342: 640–43.

US Food and Drug Administration. Statistical guidance on reporting results from studies evaluating diagnostic tests, 2007. Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071148.htm (accessed 21 February 2013).

Linnet K Boyd JC . Selection and analytical evaluation of methods with statistical techniques. In Burtis CA Ashwood ER Bruns DE (eds). Tietz Textbook of Clinical Chemistry and Molecular Diagnostics (5th edn). Elsevier Saunders, St Louis, MO, 2012, pp. 7–47.

NCCLS. Evaluation of Precision Performance of Quantitative Methods: Approved Guideline – Second Edition (NCCLS document EP5–A2). NCCLS, Wayne, PA, 2004.

NCCLS. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach: Approved Guideline (NCCLS document EP6-A). NCCLS, Wayne, PA, 2003.

CLSI. Method Comparison and Bias Estimation Using Patient Samples: Approved Guideline – Second Edition (Interim Revision) (CLSI document EP09-A2-IR). Clinical and Laboratory Standards Institute, Wayne, PA, 2010.

CLSI. User Protocol for Evaluation of Qualitative Test Performance (CLSI document EP12-A2-IR). Clinical and Laboratory Standards Institute, Wayne, PA, 2008.

CLSI. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures: Approved Guideline – Second Edition (CLSI document EP17-A2). Clinical and Laboratory Standards Institute, Wayne, PA, 2012.

CLSI. Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory: Approved Guideline (CLSI document C28-A3). Clinical and Laboratory Standards Institute, Wayne, PA, 2008.

CLSI. Expression of Measurement Uncertainty in Laboratory Medicine: Approved Guideline (CLSI document C51-A). Clinical and Laboratory Standards Institute, Wayne, PA, 2012.

CLSI. Quality Assurance for Design Control and Implementation of Immunohistochemistry Assays: Approved Guideline – Second Edition (CLSI document I/LA28-A2). Clinical and Laboratory Standards Institute, Wayne, PA, 2011.

Clinical and Laboratory Standards Institute. Harmonized terminology database. Available at: http://login.clsi.org/HTDatabase.cfm (accessed 1 March 2013).

Dybkaer R . Vocabulary for use in measurement procedures and description of reference materials in laboratory medicine. Eur J Clin Chem Clin Biochem 1997; 35: 141–73.

ISO/IEC. International Vocabulary of Metrology – Basic and General Concepts and Associated Terms (VIM) (ISO/IEC Guide 99). International Organization for Standardization, Geneva, 2007.

Sanger F Nicklen S Coulson AR . DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977; 74(12): 5463–67.

Linnet K . Estimation of the limit of detection with a bootstrap-derived standard error by a partly non-parametric approach. Application to HPLC drug assays. Clin Chem Lab Med 2005; 43(4): 394–99.

Aitchison J Dunsmore IR . Statistical Prediction Analysis. Cambridge University Press, Cambridge, 1975.

Burns M Valdivia H . Modelling the limit of detection in real-time quantitative PCR. Eur Food Res Technol 2008; 226: 1513–24.

US Food and Drug Administration. Summary of safety and effectiveness data, cobas^® 4800 BRAF V600 Mutation Test (SSED), Roche Molecular Systems, Inc., 2012. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf11/P110020b.pdf (accessed 6 February 2013).

Dempster AP Rubin DB Tsutakawa RK . Estimation in covariance component models. J Am Stat Assoc 1981; 76: 341–53.

Harville DA . Maximum likelihood approaches to variance component estimation and to related problems. J Am Stat Assoc 1977; 72: 320–40.

Laird NM Ware JH . Random-effects models for longitudinal data. Biometrics 1982; 38(4): 963–74.

US Food and Drug Administration. 510(k) substantial equivalence determination decision summary, OVA1™ Test, Vermillion, Inc., 2009. Available at: http://www.accessdata.fda.gov/cdrh_docs/reviews/K081754.pdf (accessed 21 February 2013).

Fryback DG Thornbury JR . The efficacy of diagnostic imaging. Med Decis Making 1991; 11(2): 88–94.

Gluud C Gluud LL . Evidence based diagnostics. BMJ 2005; 330(26): 724–26.

Hlatky MA Greenland P Arnett DK . Criteria for evaluation of novel markers of cardiovascular risk. Circulation 2009; 119(17): 2408–16.

Pepe MS Etzioni R Feng Z . Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93(14): 1054–61.

Sackett D Haynes RB . The architecture of diagnostic research. BMJ 2002; 324: 539–41.

Haddow JE Palomaki GE . ACCE: A model process for evaluating data on emerging genetic tests. In Khoury M Little J Burke W (eds). Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. Oxford University Press, Oxford, 2003, pp. 217–33.

Moons KGM . Criteria for scientific evaluation of novel markers: A perspective. Clin Chem 2010; 56(4): 537–41.

Zweig MH Campbell G . Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39(4): 561–77.

Januzzi JL Jr Camargo CA Anwaruddin S . The N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Am J Cardiol 2005; 95: 948–954.

US Food and Drug Administration. 510(k) substantial equivalence determination decision summary, Galectin-3, BG Medicine, Inc., 2010. Available at: http://www.accessdata.fda.gov/cdrh_docs/reviews/K093758.pdf (accessed 21 February 2013).

Steyerberg EW Vickers AJ Cook NR . Assessing performance of prediction models a framework for traditional novel measures. Epidemiology 2010; 21: 128–38.

Mandrekar SJ Sargent DJ . Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 2009; 27: 4027–34.

Janes H Pepe MS Bossuyt PM Barlow WE . Measuring the performance of markers for guiding treatment decisions. Ann Intern Med 2011; 154: 253–59.

Permutt T . A note on stratification in clinical trials. Drug Inf J 2007; 41: 719–22.

Maitournam A Simon R . On the efficiency of targeted clinical trials. Stat Med 2005; 24: 329–39.

Denne JS Pennello G Zhao L Chang SC Althouse S . Bridging clinical efficacy from a laboratory developed assay to a validated in vitro diagnostic test kit used to identify a subpopulation for a tailored therapy. Stat Biopharm Res, submitted.

Mack GS . FDA holds court on post hoc data linking KRAS status to drug response. Nat Biotechnol 2009; 27(2): 110–12.

Simon RM Paik S Hayes DF . Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101(21): 1446–52.

Subramanian J Simon R . What should physicians look for in evaluating prognostic gene-expression signatures? Nat Rev Clin Oncol 2010; 7: 327–34.

Carroll RJ Ruppert D Stefanski LA Crainiceanu CM . Measurement Error in Nonlinear Models: A Modern Perspective. Chapman Hall/CRC, Boca Raton, FL, 2006.

Burtis CA Ashwood ER Bruns DE (eds). Tietz Textbook of Clinical Chemistry and Molecular Diagnostics (5th edn). Elsevier Saunders, St Louis, MO, 2012.

Kuha J Skinner C Palmgren J . Misclassification error. In Armitage P Colton T (eds). Encyclopedia of Biostatistics (2nd edn). Wiley, Hoboken, NJ, 2010, pp. 3257–64.